James Wooldridge
Director Técnico/Científico/I+D en CHECKMATE PHARMACEUTICALS, INC. .
Cargos activos de James Wooldridge
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| CHECKMATE PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 01/10/2019 | - |
Historial de carrera de James Wooldridge
Antiguos cargos conocidos de James Wooldridge.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| SPYRE THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 10/07/2017 | 10/10/2019 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/01/2006 | - |
Formación de James Wooldridge.
| William Jewell College | Undergraduate Degree |
| Tulane University (Louisiana) | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 6 |
Operativa
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Empresas privadas | 1 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- James Wooldridge
- Experiencia
